77 related articles for article (PubMed ID: 38645565)
1. A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues.
de Back TR; Wu T; Schafrat PJ; Ten Hoorn S; Tan M; He L; van Hooff SR; Koster J; Nijman LE; Vink GR; Beumer IJ; Elbers CC; Lenos KJ; Sommeijer DW; Wang X; Vermeulen L
Life Sci Alliance; 2024 Aug; 7(8):. PubMed ID: 38782602
[TBL] [Abstract][Full Text] [Related]
2. The Glasgow Microenvironment Score: an exemplar of contemporary biomarker evolution in colorectal cancer.
Knight K; Bigley C; Pennel K; Hay J; Maka N; McMillan D; Park J; Roxburgh C; Edwards J
J Pathol Clin Res; 2024 Jul; 10(4):e12385. PubMed ID: 38853386
[TBL] [Abstract][Full Text] [Related]
3. CSRP1 expression is associated with a mesenchymal, stroma-rich tumor profile and poor prognosis in colon cancer.
Demirkol Canli S
Turk J Med Sci; 2023; 53(6):1678-1689. PubMed ID: 38813484
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6-Positive Immune Cells as a Possible New Immunologic Marker Associated With the Colorectal Cancer Prognosis.
Gulubova M; Chonov D; Aleksandrova E; Ivanova K; Ignatova MM; Vlaykova T
Appl Immunohistochem Mol Morphol; 2024 May-Jun 01; 32(5):233-243. PubMed ID: 38712586
[TBL] [Abstract][Full Text] [Related]
5. Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine.
Mouillet-Richard S; Cazelles A; Sroussi M; Gallois C; Taieb J; Laurent-Puig P
Clin Cancer Res; 2024 Jun; 30(11):2351-2358. PubMed ID: 38564259
[TBL] [Abstract][Full Text] [Related]
6. Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.
Sirinukunwattana K; Domingo E; Richman SD; Redmond KL; Blake A; Verrill C; Leedham SJ; Chatzipli A; Hardy C; Whalley CM; Wu CH; Beggs AD; McDermott U; Dunne PD; Meade A; Walker SM; Murray GI; Samuel L; Seymour M; Tomlinson I; Quirke P; Maughan T; Rittscher J; Koelzer VH;
Gut; 2021 Mar; 70(3):544-554. PubMed ID: 32690604
[TBL] [Abstract][Full Text] [Related]
7. Multiregional transcriptomics identifies congruent consensus subtypes with prognostic value beyond tumor heterogeneity of colorectal cancer.
Langerud J; Eilertsen IA; Moosavi SH; Klokkerud SMK; Reims HM; Backe IF; Hektoen M; Sjo OH; Jeanmougin M; Tejpar S; Nesbakken A; Lothe RA; Sveen A
Nat Commun; 2024 May; 15(1):4342. PubMed ID: 38773143
[TBL] [Abstract][Full Text] [Related]
8. Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer.
Malla SB; Byrne RM; Lafarge MW; Corry SM; Fisher NC; Tsantoulis PK; Mills ML; Ridgway RA; Lannagan TRM; Najumudeen AK; Gilroy KL; Amirkhah R; Maguire SL; Mulholland EJ; Belnoue-Davis HL; Grassi E; Viviani M; Rogan E; Redmond KL; Sakhnevych S; McCooey AJ; Bull C; Hoey E; Sinevici N; Hall H; Ahmaderaghi B; Domingo E; Blake A; Richman SD; Isella C; Miller C; Bertotti A; Trusolino L; Loughrey MB; Kerr EM; Tejpar S; ; Maughan TS; Lawler M; Campbell AD; Leedham SJ; Koelzer VH; Sansom OJ; Dunne PD
Nat Genet; 2024 Mar; 56(3):458-472. PubMed ID: 38351382
[TBL] [Abstract][Full Text] [Related]
9. Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients.
Bugada D; Allegri M; Lavand'homme P; De Kock M; Fanelli G
Biomed Res Int; 2014; 2014():142425. PubMed ID: 24877056
[TBL] [Abstract][Full Text] [Related]
10. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
Rebersek M
Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
[TBL] [Abstract][Full Text] [Related]
11. The potential role of platelets in the consensus molecular subtypes of colorectal cancer.
Lam M; Roszik J; Kanikarla-Marie P; Davis JS; Morris J; Kopetz S; Menter DG
Cancer Metastasis Rev; 2017 Jun; 36(2):273-288. PubMed ID: 28681242
[TBL] [Abstract][Full Text] [Related]
12. Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer.
Jakab A; Patai ÁV; Darvas M; Tormássi-Bély K; Micsik T
Pathol Oncol Res; 2024; 30():1611574. PubMed ID: 38645565
[No Abstract] [Full Text] [Related]
13. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
14. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
[TBL] [Abstract][Full Text] [Related]
15. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
